enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Teriparatide - Wikipedia

    en.wikipedia.org/wiki/Teriparatide

    Teriparatide, sold under the brand name Forteo, is a form of parathyroid hormone (PTH) consisting of the first 34 amino acids, which is the bioactive portion of the hormone. [13] It is an effective anabolic (promoting bone formation) agent [ 15 ] used in the treatment of some forms of osteoporosis .

  3. Palopegteriparatide - Wikipedia

    en.wikipedia.org/wiki/Palopegteriparatide

    The US Food and Drug Administration (FDA) prescription label for palopegteriparatide includes warnings for a potential risk of risk of unintended changes in serum calcium levels related to number of daily injections and total delivered dose, serious hypocalcemia and hypercalcemia (blood calcium levels that are too high), osteosarcoma (a rare bone cancer) based on findings in rats, orthostatic ...

  4. Osteoporosis - Wikipedia

    en.wikipedia.org/wiki/Osteoporosis

    The US National Osteoporosis Foundation recommends pharmacologic treatment for patients with hip or spine fracture thought to be related to osteoporosis, those with BMD 2.5 SD or more below the young normal mean (T-score -2.5 or below), and those with BMD between 1 and 2.5 SD below normal mean whose 10-year risk, using FRAX, for hip fracture is ...

  5. File:Teriparatide structure.svg - Wikipedia

    en.wikipedia.org/wiki/File:Teriparatide...

    English: Skeletal formula of teriparatide—recombinant 34 N-terminal amino acids (the biologically active region) of the 84-amino acid human parathyroid hormone. Created with ChemDoodle 7.0.2 and Adobe Illustrator CC.

  6. Abaloparatide - Wikipedia

    en.wikipedia.org/wiki/Abaloparatide

    Additionally, greater BMD increase at 6, 12 and 18 months in spinal, hips and femoral bones was observed in abaloparatide compared to placebo and teriparatide-treated subjects. [ 21 ] Participants who completed 18 months of abaloparatide or placebo in the ACTIVE study were invited to participate in an extended open-labeled study - ACTIVExtend ...